Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25A | P30304 | 10/20 | 1.00 |
| ▸ | CES1 | P23141 | 5/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.97 |
| ▸ | ALDH2 | P05091 | 2/20 | 0.97 |
| ▸ | ALDH3A1 | P30838 | 2/20 | 0.97 |
| ▸ | BCHE | P06276 | 2/20 | 0.69 |
| ▸ | PKM | P14618 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28299129 | 1.00 | CDC25A (1.00) | CDC25ACES1ALDH1A1ALDH2ALDH3A1 | |
| SCHEMBL29613389 | 1.00 | CDC25A (1.00) | CDC25ACES1ALDH1A1ALDH2ALDH3A1 | |
| SCHEMBL12930216 | 1.00 | CDC25A (1.00) | CDC25ACES1ALDH1A1ALDH2ALDH3A1 | |
| SCHEMBL29821573 | 1.00 | CDC25A (1.00) | CDC25ACES1ALDH1A1ALDH2ALDH3A1 | |
| SCHEMBL3016105 | 1.00 | CDC25A (1.00) | CDC25ACES1ALDH1A1ALDH2ALDH3A1 | |
| SCHEMBL281625 | 0.98 | ALDH1A1 (1.00) | CDC25ACES1ALDH1A1ALDH2ALDH3A1 | |
| SCHEMBL3019788 | 0.93 | ALDH1A1 (0.90) | CDC25ACES1ALDH1A1ALDH2ALDH3A1 | |
| SCHEMBL25119255 | 0.92 | CES1 (0.84) | CDC25ACES1ALDH1A1ALDH2ALDH3A1 | |
| SCHEMBL25119569 | 0.90 | CES1 (0.85) | CDC25ACES1ALDH1A1ALDH2ALDH3A1 | |
| SCHEMBL30382960 | 0.87 | CDC25A (0.77) | CDC25ACES1ALDH1A1ALDH2ALDH3A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110903449-B | Isatin arene copolymer, preparation method and application | 大连理工大学 | 2022-09-06 | — | — | CN | disclosed |
| CN-108299137-B | Selective fluorination method of isatin hydrazone compound | 中南大学 | 2020-04-14 | — | — | CN | disclosed |
| CN-110903449-A | Isatin arene copolymer, preparation method and application | 大连理工大学 | 2020-03-24 | — | — | CN | disclosed |
| CN-109679367-A | Vickery blue and preparation method thereof | 浙江理工大学 | 2019-04-26 | — | — | CN | disclosed |
| CN-108299137-A | A kind of isatin hydrazone compounds selective fluorination method | 中南大学 | 2018-07-20 | — | — | CN | disclosed |
| US-20180200225-A1 | HYDRAZONE MODULATORS OF CANNABINOID RECEPTORS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2018-07-19 | — | — | US | disclosed |
| EP-3241834-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2017-11-08 | — | — | EP | disclosed |
| US-20170231953-A1 | HYDRAZONE MODULATORS OF CANNABINOID RECEPTORS | CLEVELAND CLINIC FOUND (US) | 2017-08-17 | — | — | US | disclosed |
| US-9656957-B2 | Hydrazone modulators of cannabinoid receptors | THE CLEVELAND CLINIC FOUNDATION (US) | 2017-05-23 | — | — | US | disclosed |
| US-9315484-B2 | Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof | The Board of Trustees—Leland Stanford Junior University (US) | 2016-04-19 | — | — | US | disclosed |
| WO-2008112164-A2 | MITOCHONDRIAL ALDEHYDE DEHYDROGENASE-2 MODULATORS AND METHODS OF USE THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008060789-A2 | USE OF SPIRO-OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008046083-A2 | USE OF OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2008-04-17 | — | — | WO | disclosed |
| EP-1888595-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2008-02-20 | — | — | EP | disclosed |
| EP-1877378-A2 | OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2008-01-16 | — | — | EP | disclosed |
| WO-2007132280-A1 | ISATIN AND ITS DERIVATIVES FOR USE AS A MEDICAMENT | Szegedi Tudományegyetem (HU) | 2007-11-22 | — | — | WO | disclosed |
| US-20070105820-A1 | Oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2007-05-10 | — | — | US | disclosed |
| US-20060252812-A1 | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2006-11-09 | — | — | US | disclosed |
| WO-2006113864-A2 | OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-10-26 | — | — | WO | disclosed |
| WO-2006110917-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105820-A1 | Oxindole compounds and their uses as therapeutic agents | OPRL1, OPRK1, TRPV1 | CDC25A 3151/4885CES1 4183/4885ALDH1A1 1136/4885 |
| US-20170231953-A1 | HYDRAZONE MODULATORS OF CANNABINOID RECEPTORS | CNR1, CNR2, GPR18 | CDC25A 2577/4885CES1 1610/4885ALDH1A1 2096/4885 |
| US-20060252812-A1 | Spiro-oxindole compounds and their uses as therapeutic agents | OPRK1, OPRD1, SCN3A | CDC25A 947/4885CES1 3669/4885ALDH1A1 838/4885 |
| US-20180200225-A1 | HYDRAZONE MODULATORS OF CANNABINOID RECEPTORS | CNR1, CNR2, GPR18 | CDC25A 2577/4885CES1 1610/4885ALDH1A1 2096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.